Johnson & Johnson (NYSE:JNJ) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. On December 26, Johnson & ...

Children conceived through assisted reproductive technology (ART) were modestly more likely to develop asthma, allergic ...

The drug JNJ-5939 was being evaluated in the treatment of moderate to severe atopic dermatitis in a mid-stage study. ・JNJ, ...

Nemolizumab, which targets the interleukin-31 pathway, rapidly improves itch and sleep in people with atopic dermatitis and ...

Johnson & Johnson said on Friday it discontinued a mid-stage study of its experimental drug to treat patients with moderate ...

Iron deficiency without anemia is a common feature of moderate-to-severe atopic dermatitis (AD), according to a study ...

Adults with atopic eczema are significantly more likely to experience suicidal thoughts than those without the skin condition ...

Due to eczema, asthma and allergies being so closely connected, coordinated care plays a critical role in long-term outcomes. Allergists are uniquely trained to manage these conditions together rather ...

A recently approved injectable eczema drug provides quick itch relief to patients with the maddening skin disease, a new ...

Once limited to nonspecific anti-inflammatory therapies, expanding treatment options for atopic dermatitis are allowing therapy to be individualized.

A new study from North Carolina State University found that neutrophils—white blood cells that are a key part of the immune ...